Directorio

We are doing this study to find out if a study drug called binimetinib is a safe and effective option for cancers that harbor certain genetic mutations (RAS/RAF/MEK). We want to know how well it works on its own for some cancers, and how it works in combination with another study drug called palbociclib for other cancers.

We are doing this study to compare the outcomes for women who use selumetinib alone and women who use selumetinib plus olaparib to treat endometrial or ovarian cancer. We want to know which option is better for women whose tumors harbor a mutation in a key survival pathway called KRAS.

We are doing this study to find out if combining a drug called ipatasertib with the chemotherapy drug paclitaxel can help shrink or control solid tumors that have AKT gene mutations.

We are doing this study to find out if a drug called pembrolizumab (the study drug) is a safe and effective option for people with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma. We want to know if adding it to treatment with the usual drug for this type of cancer can improve results.

The Endometrial Cancer Molecularly Targeted Therapy Consortium is a multi-institutional alliance that is developing a cancer data and tissue repository. The information in this repository will be used to better understand tumor alterations and cancer biomarkers that can help us develop new therapies and potentially improve survival outcomes for women with endometrial cancer.

We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with estrogen receptor positive (ER+) breast cancer.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

We are doing this study to find out if a drug called fluoxetine (the study drug) can cause changes to structures in your cells called lysosomes that then improve how well the chemotherapy drug temozolomide (TMZ) kills cancer cells in the brain. Lysosomes are organelles (structures in cells) that contain digestive enzymes (substances that break down chemicals) that help keep the cells free of extra or worn out cell parts. The study drug is approved by the FDA to treat problems like depression and anxiety, but we do not know if it also might be beneficial in treating cancer.